GlassScriptPhysician profile
John Richard Nicholson
NPI 1548550833
$9,222.51
in general payments reported to CMS, 2019-2025
67 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,048 · 2020: $743 · 2021: $554 · 2022: $2,102 · 2023: $1,158 · 2024: $1,337 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,565 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,564.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,773.27 | 2019-2025 | Lynparza, Calquence, Enhertu |
| Novartis Pharmaceuticals Corporation | $618.54 | 2019-2025 | |
| Pfizer INC. | $603.51 | 2019-2025 | |
| Amgen INC. | $522.49 | 2019-2023 | Kyprolis, Blincyto |
| Seagen INC. | $474.91 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Janssen Biotech, INC. | $459.12 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Welch Allyn | $432.31 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $422.64 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Daiichi Sankyo INC. | $280.72 | 2019-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $271.33 | 2019-2025 | Keytruda, Keytruda Qlex |
| Celgene Corporation | $258.32 | 2020-2025 | Reblozyl, Pomalyst |
| Eisai INC. | $185.68 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.72 | 2019-2025 | Stiolto Respimat, Spiriva Respimat, Gilotrif |
| Incyte Corporation | $159.60 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Genzyme Corporation | $144.23 | 2019-2025 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nicholson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.